|
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.ss) DCF Avaliação
CN | Healthcare | Drug Manufacturers - General | SHH
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) Bundle
Procurando determinar o valor intrínseco de Zhangzhou Pientzehuang Pharmaceutical, Ltd? Nossa calculadora DCF (600436SS) integra dados do mundo real com recursos abrangentes de personalização, permitindo refinar suas previsões e aprimorar suas opções de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,722.3 | 6,510.8 | 8,021.6 | 8,694.0 | 10,058.5 | 11,594.0 | 13,363.8 | 15,403.9 | 17,755.3 | 20,465.7 |
| Revenue Growth, % | 0 | 13.78 | 23.2 | 8.38 | 15.69 | 15.27 | 15.27 | 15.27 | 15.27 | 15.27 |
| EBITDA | 1,731.5 | 2,074.4 | 3,048.3 | 3,124.7 | 3,575.6 | 3,979.3 | 4,586.8 | 5,287.0 | 6,094.0 | 7,024.3 |
| EBITDA, % | 30.26 | 31.86 | 38 | 35.94 | 35.55 | 34.32 | 34.32 | 34.32 | 34.32 | 34.32 |
| Depreciation | 66.6 | 102.7 | 149.5 | 95.7 | 102.4 | 155.9 | 179.7 | 207.1 | 238.7 | 275.2 |
| Depreciation, % | 1.16 | 1.58 | 1.86 | 1.1 | 1.02 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 |
| EBIT | 1,664.9 | 1,971.8 | 2,898.9 | 3,029.0 | 3,473.3 | 3,823.4 | 4,407.1 | 5,079.9 | 5,855.3 | 6,749.2 |
| EBIT, % | 29.1 | 30.28 | 36.14 | 34.84 | 34.53 | 32.98 | 32.98 | 32.98 | 32.98 | 32.98 |
| Total Cash | 4,263.4 | 5,168.5 | 7,105.6 | 2,496.4 | 10,173.0 | 8,607.0 | 9,920.9 | 11,435.4 | 13,181.0 | 15,193.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 486.9 | 574.3 | 673.3 | 859.5 | 1,021.2 | 1,061.2 | 1,223.2 | 1,409.9 | 1,625.1 | 1,873.2 |
| Account Receivables, % | 8.51 | 8.82 | 8.39 | 9.89 | 10.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 |
| Inventories | 2,097.0 | 2,190.9 | 2,437.5 | 2,627.8 | 3,378.7 | 3,814.4 | 4,396.7 | 5,067.9 | 5,841.5 | 6,733.2 |
| Inventories, % | 36.65 | 33.65 | 30.39 | 30.23 | 33.59 | 32.9 | 32.9 | 32.9 | 32.9 | 32.9 |
| Accounts Payable | 260.8 | 239.9 | 387.0 | 466.5 | 667.9 | 581.4 | 670.2 | 772.5 | 890.4 | 1,026.3 |
| Accounts Payable, % | 4.56 | 3.69 | 4.82 | 5.37 | 6.64 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 |
| Capital Expenditure | -65.4 | -419.0 | -92.2 | -175.4 | -141.9 | -281.9 | -324.9 | -374.5 | -431.7 | -497.6 |
| Capital Expenditure, % | -1.14 | -6.44 | -1.15 | -2.02 | -1.41 | -2.43 | -2.43 | -2.43 | -2.43 | -2.43 |
| Tax Rate, % | 16.97 | 16.97 | 16.97 | 16.97 | 16.97 | 16.97 | 16.97 | 16.97 | 16.97 | 16.97 |
| EBITAT | 1,391.4 | 1,665.5 | 2,457.2 | 2,514.9 | 2,884.0 | 3,203.0 | 3,691.9 | 4,255.5 | 4,905.2 | 5,653.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -930.6 | 1,146.9 | 2,316.0 | 2,138.2 | 2,133.3 | 2,514.8 | 2,891.2 | 3,332.5 | 3,841.3 | 4,427.7 |
| WACC, % | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 | 7.93 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 13,316.8 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 4,605 | |||||||||
| Terminal Value | 117,188 | |||||||||
| Present Terminal Value | 80,018 | |||||||||
| Enterprise Value | 93,334 | |||||||||
| Net Debt | -26 | |||||||||
| Equity Value | 93,360 | |||||||||
| Diluted Shares Outstanding, MM | 603 | |||||||||
| Equity Value Per Share | 154.86 |
What You Will Receive
- Authentic 600436SS Financial Data: Pre-loaded with Zhangzhou Pientzehuang Pharmaceutical's historical and forecasted data for accurate analysis.
- Completely Customizable Template: Easily adjust essential inputs such as revenue growth, WACC, and EBITDA percentage.
- Instant Calculations: Watch as the intrinsic value of Zhangzhou Pientzehuang updates in real-time based on your modifications.
- Professional Valuation Resource: Tailored for investors, analysts, and consultants aiming for precise DCF results.
- User-Friendly Layout: Intuitive design and straightforward guidance suitable for users of all skill levels.
Key Features
- Real-Life 600436SS Data: Pre-filled with Zhangzhou Pientzehuang Pharmaceutical’s historical financials and future growth projections.
- Fully Customizable Inputs: Tailor revenue growth, profit margins, discount rates, tax rates, and capital expenditures to your preferences.
- Dynamic Valuation Model: Automatically updates the Net Present Value (NPV) and intrinsic value based on your entered data.
- Scenario Testing: Generate various forecast scenarios to explore different valuation outcomes.
- User-Friendly Design: Intuitive, organized layout suitable for both professionals and newcomers.
How It Functions
- 1. Access the Template: Download and open the Excel file featuring Zhangzhou Pientzehuang Pharmaceutical, Ltd's (600436SS) preloaded data.
- 2. Adjust Assumptions: Modify essential inputs such as growth rates, WACC, and capital expenditures.
- 3. View Immediate Results: The DCF model automatically calculates intrinsic value and NPV.
- 4. Explore Different Scenarios: Analyze various forecasts to assess different valuation outcomes.
- 5. Utilize with Assurance: Present expert valuation insights to bolster your decision-making.
Why Opt for This Calculator?
- All-in-One Solution: Features DCF, WACC, and financial ratio analyses all in one convenient tool.
- Flexible Inputs: Modify the highlighted cells to explore different scenarios.
- In-Depth Analysis: Automatically computes the intrinsic value and Net Present Value for Zhangzhou Pientzehuang Pharmaceutical (600436SS).
- Preloaded Information: Comes with historical and projected data for a solid foundation.
- High-Caliber Quality: Perfect for financial analysts, investors, and business consultants.
Who Can Benefit from This Product?
- Investors: Effectively evaluate the fair value of Zhangzhou Pientzehuang Pharmaceutical (600436SS) before making investment choices.
- CFOs: Utilize a high-quality DCF model for accurate financial reporting and analysis.
- Consultants: Efficiently modify the template for client valuation reports.
- Entrepreneurs: Acquire knowledge on financial modeling practices employed by leading pharmaceutical companies.
- Educators: Employ it as a pedagogical resource to illustrate valuation techniques.
Contents of the Template
- Preloaded 600436SS Data: Historical and forecasted financial information, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Advanced sheets designed for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted fields for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial reports for in-depth analysis.
- Key Ratios: Metrics for profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual presentations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.